Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 14 Mar 2023
Novo Nordisk to lower US prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024
14 March 2023 - Novo Nordisk currently provides co-pay support for a number of insulin products meaning eligible patients can pay ...
Posted by Michael Wonder on 14 Mar 2023
CEO’s appointment to HTA Review Reference Committee
15 March 2023 - CEO of Medicines Australia, Elizabeth de Somer, has been appointed as the medicines industry representative on ...
Posted by Michael Wonder on 14 Mar 2023
Veterans Affairs to be first major insurer to cover Alzheimer’s drug Leqembi
13 March 2023 - Roughly 168,000 veterans receiving care have Alzheimer’s dementia. ...
Posted by Michael Wonder on 13 Mar 2023
SMC - March 2023 decisions
13 March 2023 - The SMC which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 13 Mar 2023
Haihe Biopharma announces gumarontinib receives approval from the NMPA of China for the treatment of locally advanced or metastatic NSCLC with MET exon 14 skipping mutation
8 March 2023 - Haihe Biopharma today announced that the NMPA of China has given conditional approval to gumarontinib, an oral ...
Posted by Michael Wonder on 13 Mar 2023
Heron Therapeutics announces Centers for Medicare & Medicaid Services granted pass through payment status for Aponvie
13 March 2023 - Heron Therapeutics today announced that CMS has approved transitional pass-through status for Aponvie (aprepitant) injectable emulsion, which ...
Posted by Michael Wonder on 13 Mar 2023
Harrow announces transitional pass through reimbursement status for Iheezo (chloroprocaine hydrochloride 3% ophthalmic gel)
13 March 2023 - Harrow today announced that the Centers for Medicare & Medicaid Services has approved transitional pass-through reimbursement ...
Posted by Michael Wonder on 12 Mar 2023
Medicare doesn’t pay for obesity drugs: lifting this coverage prohibition faces considerable hurdles
11 March 2023 - A number of different stakeholders across the healthcare landscape are lobbying legislators and the Centers for Medicare ...
Posted by Michael Wonder on 12 Mar 2023
The value of medical innovation versus industry rewards
10 March 2023 - This article provides systematic evidence on the share of the value of health generated by drugs and ...
Posted by Michael Wonder on 12 Mar 2023
By cutting insulin prices, Eli Lilly avoids paying big Medicaid rebates
6 March 2023 - Eli Lilly would’ve had to pay Medicaid about $150 for each vial of insulin used in ...
Posted by Michael Wonder on 12 Mar 2023
‘When’s our turn?’ PHARMAC's new funding won't cover breast cancer fighter's $100k bill
13 March 2023 - Hayley Steele has a hefty price tag on her life, one worth almost $100,000. ...
Posted by Michael Wonder on 12 Mar 2023
Medicare Part D coverage of anti-obesity medications — challenges and uncertainty ahead
11 March 2023 - Obesity is highly prevalent in the United States — affecting more than 41% of adults, including a ...
Posted by Michael Wonder on 11 Mar 2023
Drug pricing throughout the product lifecycle: a work in progress
10 March 2023 - Increases in drug prices and drug spending are of concern to health systems worldwide. This has naturally ...
Posted by Michael Wonder on 11 Mar 2023
Maxigesic Rapid tablets gain US FDA approval
10 March 2023 - AFT Pharmaceuticals today announces the US FDA has approved a rapid release tablet form of Maxigesic ...
Posted by Michael Wonder on 11 Mar 2023
COVID-19 vaccine safety report (9 March 2023)
9 March 2023 - To 5 March 2023, over 44 million doses have been administered in Australia, as well as about ...